Literature DB >> 15933557

Antimicrobial-resistant Shigella sonnei: limited antimicrobial treatment options for children and challenges of interpreting in vitro azithromycin susceptibility.

Sanjay K Jain1, Amita Gupta, Brian Glanz, James Dick, George K Siberry.   

Abstract

BACKGROUND: Antimicrobial-resistant Shigella sonnei is a growing problem in the United States and poses treatment challenges particularly among children. Azithromycin is recommended as an alternative oral agent for shigellosis.
METHODS: All isolates of Shigella submitted to Johns Hopkins clinical laboratory during the outbreak year (2002) were compared with a historical comparison group (1996-2000). Isolates were considered multiresistant if they were resistant to ampicillin and trimethoprim-sulfamethoxazole (TS). Selected outbreak and reference isolates were tested for azithromycin susceptibility by E-test, disk diffusion and broth dilution methods.
RESULTS: Between 1996-2000, among the 111 isolates submitted, 63% were from pediatric patients; 63% of isolates were resistant to ampicillin and 12% to TS. In 2002, among the 205 isolates submitted, 82% were from pediatric patients; 91% isolates were resistant to ampicillin and 67% to TS. The proportion of multiresistant isolates increased from 6% in 1996 to 65% in 2002 (P < 0.05). Azithromycin susceptibility by E-test and disk diffusion demonstrated 2 zones of inhibition for S. sonnei. Interpretation using the inner zone resulted in higher MICs (minimal inhibitory concentration) compared with the outer zones by E-test (P < 0.0001) and disk diffusion (P < 0.0001).
CONCLUSIONS: With increasing interest in using azithromycin for shigellosis, clinical laboratories should be aware of the interpretation difficulty caused by the dual-zone phenomenon seen with E-test and disk diffusion methods for S. sonnei.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15933557     DOI: 10.1097/01.inf.0000164707.13624.a7

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  15 in total

1.  Comparative analysis of antimicrobial resistance in enterotoxigenic Escherichia coli isolates from two paediatric cohort studies in Lima, Peru.

Authors:  Anicia M Medina; Fulton P Rivera; Maria J Pons; Maribel Riveros; Cláudia Gomes; María Bernal; Rina Meza; Ryan C Maves; Luis Huicho; Elsa Chea-Woo; Claudio F Lanata; Ana I Gil; Theresa J Ochoa; Joaquim Ruiz
Journal:  Trans R Soc Trop Med Hyg       Date:  2015-08       Impact factor: 2.184

2.  Options for treating resistant Shigella species infections in children.

Authors:  Sharon M Erdman; Elizabeth E Buckner; Janet F Hindler
Journal:  J Pediatr Pharmacol Ther       Date:  2008-01

3.  Evaluation of Shigella Species Azithromycin CLSI Epidemiological Cutoff Values and Macrolide Resistance Genes.

Authors:  Muna Salah; Issa Shtayeh; Raed Ghneim; Randa Al-Qass; Ali Sabateen; Hiyam Marzouqa; Musa Hindiyeh
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

4.  Effect of trimethoprim-sulfamethoxazole prophylaxis on antimicrobial resistance of fecal Escherichia coli in HIV-infected patients in Tanzania.

Authors:  Susan C Morpeth; Nathan M Thielman; Habib O Ramadhani; John D Hamilton; Jan Ostermann; Peter R Kisenge; Humphrey J Shao; L Barth Reller; Dafrosa K Itemba; Noel E Sam; John A Bartlett; John F Shao; John A Crump
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-15       Impact factor: 3.731

Review 5.  Part II. Analysis of data gaps pertaining to Shigella infections in low and medium human development index countries, 1984-2005.

Authors:  P K Ram; J A Crump; S K Gupta; M A Miller; E D Mintz
Journal:  Epidemiol Infect       Date:  2007-08-09       Impact factor: 2.451

6.  Macrolide-resistant Shigella sonnei.

Authors:  Leyla Boumghar-Bourtchai; Patricia Mariani-Kurkdjian; Edouard Bingen; Ingrid Filliol; Anne Dhalluin; Shadia Ait Ifrane; François-Xavier Weill; Roland Leclercq
Journal:  Emerg Infect Dis       Date:  2008-08       Impact factor: 6.883

7.  Novel extended-spectrum beta-lactamase in Shigella sonnei.

Authors:  Agnes Lefort; Guillaume Arlet; Olivier F Join-Lambert; Marc Lecuit; Olivier Lortholary
Journal:  Emerg Infect Dis       Date:  2007-04       Impact factor: 6.883

8.  A unified approach to molecular epidemiology investigations: tools and patterns in California as a case study for endemic shigellosis.

Authors:  Sawsan Al-Nimri; Woutrina A Miller; Barbara A Byrne; Gerry Guibert; Lily Chen
Journal:  BMC Infect Dis       Date:  2009-11-24       Impact factor: 3.090

9.  Prevalence of Shigella serogroups and their antimicrobial resistance patterns in southern Trinidad.

Authors:  Fitzroy A Orrett
Journal:  J Health Popul Nutr       Date:  2008-12       Impact factor: 2.000

10.  Isolation and antibiotic susceptibility of Shigella species from stool samples among hospitalized children in Abadan, Iran.

Authors:  Nabi Jomezadeh; Shahram Babamoradi; Enayatollah Kalantar; Hazhir Javaherizadeh
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.